<DOC>
	<DOC>NCT02328261</DOC>
	<brief_summary>This is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma.</brief_summary>
	<brief_title>A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>This phase 2 study is aimed to evaluate the efficacy of single-agent icotinib in patients with pretreated, advanced nasopharyngeal carcinoma. The primary endpoint is disease control rate (DCR).</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Histologically confirmed advanced NPC Patients must be platinumresistant defined as recurrence or progression of disease &lt;6 months since previous treatment with a platinum based treatment regimen. Measurable disease per RECIST Adequate organ and marrow function Capable of understanding and complying with the protocol, and written informed consent Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR Patients must not be receiving any other investigational agents Other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), or active uncontrolled infection Women who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>